Skip to main content
Journal cover image

Antibody, T-cell and dendritic cell immunotherapy for malignant brain tumors.

Publication ,  Journal Article
Chandramohan, V; Mitchell, DA; Johnson, LA; Sampson, JH; Bigner, DD
Published in: Future Oncol
July 2013

Modest improvement in brain tumor patient survival has been achieved through advances in surgical, adjuvant radiation and chemotherapeutic strategies. However, these traditional approaches have been unsuccessful in permanently controlling these aggressive tumors, with recurrence being quite common. Hence, there is a need for novel therapeutic approaches that specifically target the molecularly diverse brain tumor cell population. The ability of the immune system to recognize altered tumor cells while avoiding surrounding normal cells offers an enormous advantage over the nonspecific nature of the conventional treatment schemes. Therefore, immunotherapy represents a promising approach that may supplement the standard therapies in eliminating the residual brain tumor cells. This review summarizes different immunotherapeutic approaches currently being tested for malignant brain tumor treatment.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Future Oncol

DOI

EISSN

1744-8301

Publication Date

July 2013

Volume

9

Issue

7

Start / End Page

977 / 990

Location

England

Related Subject Headings

  • T-Lymphocytes
  • Recombinant Proteins
  • Receptors, Antigen, T-Cell
  • Radioimmunotherapy
  • Oncology & Carcinogenesis
  • Immunotoxins
  • Immunotherapy
  • Humans
  • Genetic Engineering
  • ErbB Receptors
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Chandramohan, V., Mitchell, D. A., Johnson, L. A., Sampson, J. H., & Bigner, D. D. (2013). Antibody, T-cell and dendritic cell immunotherapy for malignant brain tumors. Future Oncol, 9(7), 977–990. https://doi.org/10.2217/fon.13.47
Chandramohan, Vidyalakshmi, Duane A. Mitchell, Laura A. Johnson, John H. Sampson, and Darell D. Bigner. “Antibody, T-cell and dendritic cell immunotherapy for malignant brain tumors.Future Oncol 9, no. 7 (July 2013): 977–90. https://doi.org/10.2217/fon.13.47.
Chandramohan V, Mitchell DA, Johnson LA, Sampson JH, Bigner DD. Antibody, T-cell and dendritic cell immunotherapy for malignant brain tumors. Future Oncol. 2013 Jul;9(7):977–90.
Chandramohan, Vidyalakshmi, et al. “Antibody, T-cell and dendritic cell immunotherapy for malignant brain tumors.Future Oncol, vol. 9, no. 7, July 2013, pp. 977–90. Pubmed, doi:10.2217/fon.13.47.
Chandramohan V, Mitchell DA, Johnson LA, Sampson JH, Bigner DD. Antibody, T-cell and dendritic cell immunotherapy for malignant brain tumors. Future Oncol. 2013 Jul;9(7):977–990.
Journal cover image

Published In

Future Oncol

DOI

EISSN

1744-8301

Publication Date

July 2013

Volume

9

Issue

7

Start / End Page

977 / 990

Location

England

Related Subject Headings

  • T-Lymphocytes
  • Recombinant Proteins
  • Receptors, Antigen, T-Cell
  • Radioimmunotherapy
  • Oncology & Carcinogenesis
  • Immunotoxins
  • Immunotherapy
  • Humans
  • Genetic Engineering
  • ErbB Receptors